Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

When faced with increased workload the heart undergoes remodelling, where it increases
its muscle mass in an attempt to preserve normal function. This is referred to as cardiac …

Sodium-glucose cotransporters inhibitors (SGLT2-i) and GLP-1 receptor agonists (GLP1-
RA) are glucose-lowering drugs that are proved to reduce the cardiovascular (CV) risk in …

Oxidative stress is critically involved in the pathophysiology of myocardial ischemic-
reperfusion (I/R) injury. NADPH oxidase (Nox) 2 and 4, major sources of reactive oxygen …

Although several ribosomal protein paralogs are expressed in a tissue-specific manner, how
these proteins affect translation and why they are required only in certain tissues have …

Heart failure is an important manifestation of diabetic heart disease. Before the development
of symptomatic heart failure, as much as 50% of patients with type 2 diabetes mellitus …

Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics.
These drugs have been available on the market for the management of type 2 diabetes …

The ongoing pandemic disease named by the World Health Organization (WHO)
coronavirus disease 2019 (COVID-19), is caused by Severe Acute Respiratory Syndrome …

This study aims to investigate whether stabilization of glucagon-like peptide-1 (GLP-1) level
reduces angiotensin II (Ang II)-induced cardiac fibrosis and-elevated blood pressure …

Chronic kidney disease is a global health problem affecting 10% to 12% of the population.
Uremic cardiomyopathy is often characterized by left ventricular hypertrophy, fibrosis, and …